- Research article
- Open Access
Comparison of 99mTc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions
BMC Cancer volume 20, Article number: 463 (2020)
We sought to determine the diagnostic efficacy of Breast-specific gamma imaging (BSGI) in Chinese women with BI-RADS 4 category lesions and to compare this efficacy to that of ultrasound/mammography.
We retrospectively analyzed data from 177 women that had undergone BSGI of BI-RADS 4 category lesions originally detected via ultrasound and/or mammography.
Of these 177 cases, 117 (66.1%) were malignant lesions and 60 (33.9%) were benign. The sensitivity, specificity, positive predictive values, and negative predictive values of BSGI were 94.9% (111/117), 78.3% (47/60), 89.5% (111/124), and 88.7% (47/53), respectively. The specificity and positive predictive values for mammography were 48.3% (29/60) and 77.5% (107/138), while for ultrasound they were 53.3% (32/60) and 79.6% (109/137), respectively. The sensitivity and specificity of BSGI for the detection of lesions ≤1 cm in size were 90.9% (10/11) and 88.0% (22/25), respectively, while for breast lesions >1 cm in size these values were 94.3% (100/106) and 71.4% (25/35), respectively. In addition, BSGI sensitivity and specificity values for dense breast tissue were 94.0% (79/84) and 78.0% (39/50), respectively, whereas for non-dense breast tissue these vales were 97.0% (32/33) and 80.0% (8/10), respectively. The sensitivity of BSGI for invasive ductal carcinomas (IDC) and ductal carcinomas in situ (DCIS) was 98.9% (95/96) and 75.0% (9/12), respectively. The tumor to normal tissue ratio of BSGI for malignant lesions was significantly higher than for benign lesions (2.18 ± 1.17 vs 1.66 ± 0.40, t = 7.56, P<0.05).
These results indicate that BSGI is highly sensitive for the detection of such lesions, achieving good positive/negative predictive values. This suggests that for IDC in particular, BSGI is superior to ultrasound and mammography for the diagnosis of BI-RADS 4 category lesions, although this was less apparent for the diagnosis of DCIS lesions. BSGI exhibited excellent performance in dense breast tissue and for the detection of lesions ≤1 cm in size.
Rates of cancer have increased by nearly 28% between 2006 and 2016, with breast cancer remaining the most frequent cancer-related cause of death among women . Early-stage breast cancer diagnosis can improve patient survival. Herein we analyzed data pertaining to Breast Imaging Reporting and Data System (BI-RADS) 4 category lesions detected via ultrasound and/or mammography in order to resolve the best approach to accurately diagnosing these lesions. The BI-RADS 4 classification is intended to designate potentially suspicious masses warranting biopsy, with 3 subtypes (4a, 4b, and 4c) of increasing suspicion. These lesions, by definition, do not exhibit the morphological characteristics of breast cancer. However, they have a risk of malignancy that can range from 2 to 95% over time. This variability can lead to the unnecessary biopsy and over-treatment of benign lesions . Breast-specific gamma imaging (BSGI) is a high-resolution radioimaging approach that can be employed to visualize breast tissues using a small field-of-view gamma camera that is confined to the breast region. In this study, we evaluated the diagnostic efficacy of BSGI for the differential diagnosis of BI-RADS 4 lesions identified via ultrasound/mammography and we compared these three approaches in order to evaluate their relative diagnostic utility.
The hospital ethics committee approved this retrospective study. Written informed consent was obtained from each patient. In total, we retrospectively studied 177 patients who were diagnosed and treated at our Hospital (Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China) between January, 2015 and June, 2018. All analyzed patients had been identified as having BI-RADS 4 category masses based via ultrasound and/or mammography, and had also undergone BSGI at our Hospital. Patients who had previously undergone surgery for breast cancer were not included in this study. After imaging examinations, histopathologic confirmation was performed via surgical excision or core needle biopsy. All patients’ clinical records were reviewed, while clinicopathological characteristics including age, menstrual state, clinical stage, lesion location, tumor size and grade, and histological type were obtained from medical records at our institution.
Patients were administered 555–740 MBq of 99mTc-MIBI (Shanghai GMS Pharmaceutical Co., Ltd) through the antecubital vein contralateral to the breast lesion. Once 10 min had elapsed following tracer injection, BSGI was conducted. Patients in a sitting position were imaged with a breast-specific gamma camera (Dilon 6800; Dilon Technologies Inc., USA), allowing for the high-resolution bilateral collection of craniocaudal (CC) and mediolateral oblique (MLO) images. The acquisition time for each image was approximately 5 min, and 100,000 counts per image were defined as the minimal range. Two physicians specializing in nuclear medicine interpreted all BSGI images according to the Society of Nuclear Medicine published BSGI operation guidelines for interpreting BSGI imaging results . Positive BSGI tumors were those which were determined to either exhibit a tumor-to-normal tissue ratio (TNR) > 2.09, or to be highly suspicious. Lesions analyzed by ultrasound were determined to be positive based on suspicious appearance suggesting the need for biopsy or removal. Two radiologists interpreted all mammography images based on BI-RADS classification.
The sensitivity, specificity, positive predictive values, and negative predictive values for BSGI, ultrasound, and mammography were determined. The relative efficiencies of BSGI, ultrasound, and mammography, as well as the semi-quantitative indicators thereof, were calculated and compared via χ2 tests. SPSS v20 was used for all statistical testing, with P < 0.05 as the significance threshold.
Ultrasound and mammography
Our study included 177 patients, of whom 135 (76.3%) were diagnosed with BI-RADS 4 category lesions by ultrasound, 127 (71.8%) cases were diagnosed as having BI-RADS category 4 lesions via mammography, and 87 (49.1%) were diagnosed via both of these approaches.
Of the 177 female patients, 117 (66.1%) were ultimately found to have malignant tumors. Of those with malignant lesions, the average patient age was 53.5 years old (range: 23–89). Detected malignant lesions included invasive ductal carcinomas (IDC, n = 96), ductal carcinomas in situ (DCIS, n = 12), invasive lobular carcinomas (n = 2), malignant phyllodes tumors (n = 2), and others (n = 5). The remaining 60 (33.9%) cases proved to be benign. Of patients with benign lesions, the average age was 47.2 years old (range: 19–74). Benign lesions included fibroadenomas (n = 31), adenosis (n = 17), intraductal papillomas (n = 7), and others (n = 5).
Diagnosis via BSGI, ultrasound, and mammography
The TNR cut-off for sensitivity and specificity was 2.09 (Sensitivity: 62.4%, Specificity: 78.6%) (Fig. 1a). We found that there was a statistically valid correlation between lesion malignancy and TNR ratio. The TNR ratio for the malignant group was 2.18 ± 1.17, while the TNR ratio for the benign group was 1.66 ± 0.40 (t = 7.56, P<0.05). The sensitivity of BSGI, mammography, and ultrasound for malignant lesion detection reached 94.9, 91.5, and 93.2%, respectively. BSGI had the greatest specificity at 78.3%, compared to mammography (48.3%, P < 0.05) and ultrasound (53.3%, P < 0.05) (Fig. 1b). Sensitivity and specificity findings for these imaging approaches are shown in Table 1
Malignant lesions were between 3 mm and 74 mm, with 11 lesions being smaller than 10 mm. Benign lesions were between 2 mm and 44 mm, with 25 lesions being smaller than 10 mm. The determination of tumor lesion size via surgical excision was based on pathological results. Tumor lesion size via focus of puncture was based on the results of ultrasound/ mammography. The sensitivity of BSGI was similar to that of ultrasound for lesions≤1 cm, whereas BSGI specificity was highest at 88.0%, as compared to mammography (40.0%, P < 0.05) and ultrasound (64.0%, P < 0.05) (Fig. 1c). For lesions > 1 cm in size, the specificity of BSGI was 71.4% as compared to ultrasound at 45.7% (P < 0.05) (Fig. 1d).
The American College of Radiology BI-RADS classifications are intended to offer a standardized means of reporting on the density of mammographic findings. Of these 177 subjects, 134 (75.7%) were shown to have dense breast tissue with a BI-RADS density category of 3 or 4 upon mammographic assessment. In these women, BSGI specificity was highest at 94.0%, as compared to mammography (44.0%, P < 0.05) and ultrasound (56.0%, P < 0.05) (Fig. 2a). In pre- or post-menopausal women, BSGI sensitivity was not greater than that of mammography or ultrasound, nor was there a significant difference in sensitivity between the pre- and post-menopausal groups (Fig. 2b). With respect to cancer types, the sensitivity for the detection of IDC by BSGI was superior to that of DCIS (P < 0.05). The sensitivity of BSGI was equivalent between luminal-A, luminal-B, HER2 (+), and triple-negative breast cancers (Fig. 2c). BSGI sensitivity for the detection of DCIS was similar to that of mammography or ultrasound (Fig. 2d)
False-positive and -negative BSGI findings
This study revealed 13 false-positive and 6 false-negative BSGI findings, the pathology findings of which are shown in Table 2
Several studies have shown that BSGI is highly sensitive for the detection of breast cancer in women with dense and non-dense breasts, and that it is an effective adjunct imaging modality in women with both dense and non-dense breasts . The value of this approach is highest for the detection of small carcinomas and multifocal/ multicentric disease . In this study, we explored the diagnostic efficacy of BSGI for differentiating between malignant and benign BI-RADS 4 lesions relative to that of ultrasound or mammography in Chinese women. Our results demonstrate that BSGI is well-suited to the diagnosis of suspicious lesions. Mammography is one of the primary approaches to breast cancer screening, achieving a high degree of sensitivity for the detection of breast cancer in most patients, and with its clinical implementation having led to a decline in breast cancer death rates . While mammography has become the standard means of breast cancer screening, its accuracy and sensitivity are influenced by breast density and the presence of scar tissue, with the degree of density leading to sensitivity values ranging from 85 to 68%. Breast density is also strongly correlated with the risk of breast cancer [7,8,9]. Among Chinese populations, approximately 75% of women have heterogeneously or extremely dense breasts, limiting the utility of mammography- based screening. This is particularly true in young populations in which there is a trend towards increased breast cancer incidence, and as such an alternative method of breast cancer detection is needed for this population. Unlike mammography, the sensitivity of the BSGI is not affected by breast tissue density, prosthesis implantation, structural deformation, scarring, or radiation therapy. Yu et al.  reported that the diagnostic specificity of BSGI for breast cancer was high (83.2%), and that in women with dense breast tissue BSGI was superior to mammography. Kessler et al.  reported on 93 cases of BI-RADS 4 breast lesions detected via mammography, with a positive rate of biopsy of 14%. Some special pathological types of breast cancer, such as early-stage invasive lobular carcinomas, are difficult to detect via conventional imaging approaches, whereas the detection rates for such carcinomas by BSGI are over 90% . Spanu et al  evaluated the utility of breast-specific gamma camera (BSGC) scintigraphy for DCIS identification, achieving a 93.9% sensitivity, which was slightly higher than that achieved via mammography while allowing for a better assessment of the extent of local disease. Consistent with this, in the present study, 2 invasive lobular carcinoma lesions were correctly diagnosed by BSGI (Fig. 3).
Ultrasound, as a first-line examination used to differentiate between benign and malignant breast lesions, offers the advantages of being non-invasive, convenient, and efficient. It has been widely used for the BI-RADS classification of breast lesions in the clinic. However, the utility of ultrasound for breast lesions has been varied for some types of lesions, with a lack of specificity for some, or higher false-positive detection rates . Patients with mammary intraductal papillomas typically present with nipple discharge and lumps in the area, which are characterized by a hypoechoic lesions upon ultrasound examination. Tadwalkar et al.  retrospectively analyzed BSGI findings for 139 females with invasive carcinoma. The efficiency of the BSGI-mediated diagnosis of breast cancer is related to tumor differentiation and size. In this study, for lesions≤1 cm in size the sensitivity of BSGI was similar to that of ultrasound, while the specificity of BSGI was superior to ultrasound. In addition, 4 intraductal papillomas were analyzed by ultrasound were determined to be positive based on highly suspicious appearance, yet were correctly determined to be negative via BSGI (Fig. 4).
Ultrasound and mammography are anatomical approaches to detecting breast cancer. Nuclear medicine approaches that instead rely upon the physiological characteristics of tumors are increasingly common. The detection of breast cancer can be improved by using physiological imaging as an auxiliary imaging modality. BSGI is a functional imaging test that offers better sensitivity than does traditional planar scintigraphy, particularly in patients with dense breast tissue, and it is also better for the detection of subcentimeter (< 1 cm) lesions . The radioactive tracer 99mTc-MIBI, after injection into the human body, enters into mitochondria. The number of mitochondria in cells is closely related to cell activity, and as malignant cells have a higher metabolic rate they have more mitochondria. As a result, the uptake of 99mTc-MIBI in cancer cells is greater than that in surrounding normal tissue. In vitro experiments show that tumor cells absorb 99mTc-MIBI at a rate > 50% higher than normal cells . Kim et al.  conducted a retrospective analysis of 520 suspected breast cancer patients and found that, when using a 99mTc-MIBI imaging approach, the TNR in the malignant group was 2.00 ± 1.88, which was significantly higher than in the benign group (0.60 ± 0.70). In our study, the TNR in the malignant group was 2.18 ± 1.17, which was also significantly higher than that in the benign group (1.66 ± 0.40). However, BSGI appears to be an ineffective diagnostic tool for the detection of breast cancer axillary lymph node metastasis. In a study by Spanu et al. , the authors analyzed 76 consecutive breast cancer patients, of whom 28 had axillary lymph node metastases, and they achieved true positive results via BSGU in only 7 patients (sensitivity: 25%), whereas SPECT achieved true positivity in 23 of 28 cases (sensitivity: 82.1%) and Pinpole-SPECT achieved true positivity in 25 of 28 cases (sensitivity: 89.3%) (Fig. 5).
Other modes of examination such as shear-wave elastography (SWE) and breast MRI have also been used in an effort to improve the accuracy of breast cancer diagnosis. SWE is a quantitative imaging technique widely used during breast imaging. Because breast malignant tissues are harder than normal tissues, SWE not only can locally quantify tissue hardness but also provide histological information. Yoon et al.  conducted an analysis of 199 consecutive women, demonstrating that SWE had significantly false-positive rates than false-negative rates. Size, breast thickness, and depth all influenced SWE findings. Bilimoria et al.  reported that breast MRI is the most sensitive imaging modality for detecting breast cancer, and found that it may reveal breast cancers which are difficult to detect via physical examination, mammography, or ultrasound. However, breast MRI not only has a considerable false-positive rate but also has the potential to enlarge the apparent size of the tumor in question. As a result, women assessed in this manner may undergo unnecessary mastectomy. Finally, the conventional use of breast MRI is limited by the cost of this analytical approach. In addition, the continued development of digital x-ray systems has enabled further techniques such as contrast mammography to overcome the limitations of mammography, and similar novel approaches are now being investigated. Fallenberg  et al. reported that contrast mammography is as accurate as MRI. However, this is an invasive technique, and the injection of contrast agents is not acceptable or suitable for breast cancer screening efforts.
99mTc-MIBI, as a non-specific tumor imaging agent, can yield false-positive results for certain benign hyperplastic lesions, decreasing its diagnostic performance. Fibrocystic breast disease, fibroadenomas, and breast benign hyperplasias were the most common types of false-positive lesions detected by BSGI . Malignant breast tumors can promote local angiogenesis, and some benign growths may mimic this activity, although in a manner not equivalent to that of malignant lesions. For example, some intraductal papilloma, inflammatory lesions, fibroadenomas, or adenopathies have abundant blood supplies. Inflammatory lesions also have the characteristics of inflammatory cells, with peripheral irregular infiltration of surrounding tissues. Weight et al.  reported that BSGI resulted in a higher rate of change in the management of patients (109/119) as compared with ultrasound (71/119), and found BSGI performed better than ultrasound in terms of both positive predictive value and accuracy. Overall, this study identified a total of 13 lesions with false-positive findings when analyzed via BSGI.
Limitations of BSGI
Despite its promise, there are certain limitations to the use of BSGI for breast imaging. First, during BSGI, patients were injected with 99mTc-MIBI, which is a radiopharmaceutical (555-740 MBq), leading patients to be exposed to 6.29–9.44 mSv of radiation on average [17, 24]. However, a lower injected dose of 99mTc-MIBI may be acceptable for such imaging. In a study by Rhodes et al. , when used to supplement screening mammography, BSGI conducted using 300 MBq of 99mTc-MIBI for screening (effective dose: 2.4 mSv) yielded a supplemental cancer detection rate of 8.8 per 1000 women with mammographically dense breasts, which was equivalent to the results obtained using a higher 740 MBq dose of 99mTc-MIBI, increasing the rate of cancer detection in women with mammographically dense breasts by 7.5 per 1000 screened. Patients who have suspicious lesions or dense breast tissue may be recommended for BSGI, necessitating a longer acquisition time and lower radiotracer doses. Second, as this is a planar test there is a risk of improper positioning [15, 26]. Finally, BSGI was also a relatively insensitive approach for axillary lymph node detection.
In summary, BSGI offers good diagnostic efficacy for the differential diagnosis of BI-RADS 4 category breast lesions identified via ultrasound and/or mammography. BSGI was a highly efficient means of detecting breast lesions in dense breast tissues and lesions ≤1 cm in size. These results demonstrated that BSGI may be useful as an auxiliary imaging modality for detecting suspicious lesions, and can reduce the need for unnecessary biopsy and surgical procedures, further decreasing rates of misdiagnosis, and improving the accurate diagnosis of breast cancer.
Availability of data and materials
The data involved in the current study are available upon request. Anyone who is interested in the information should contact email@example.com.
Breast specific gamma imaging
Breast imaging reporting and data system
Invasive ductal carcinomas
Ductal carcinomas in situ
Tumor-to-normal tissue ratio
Positive predictive value
Negative predictive value
Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Akinyemiju TF, Al Lami FH, Alam T, Alizadeh-Navaei R, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: a systematic analysis for the global burden of disease study. JAMA Oncol. 2018;4(11):1553–68. https://doi.org/10.1001/jamaoncol.2018.2706.
Luo J, Chen JD, Chen Q, Yue LX, Zhou G, Lan C, et al. Contrast-enhanced ultrasound improved performance of breast imaging reporting and data system evaluation of critical breast lesions. World J Radiol. 2016;8(6):610–7. https://doi.org/10.4329/wjr.v8.i6.610.
Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzkowsky L, Weigert J, et al. SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. J Nucl Med Technol. 2010;38(4):219–24. https://doi.org/10.2967/jnmt.110.082271 Epub 2010 Nov 5.
Rechtman LR, Lenihan MJ, Lieberman JH, Teal CB, Torrente J, Rapelyea JA, Brem RF. Breast-specific gamma imaging for the detection of breast cancer in dense versus nondense breasts. AJR Am J Roentgenol. 2014;202(2):293–8. https://doi.org/10.2214/AJR.13.11585.
Spanu A, Sanna D, Chessa F, Manca A, Cottu P, Fancellu A, Nuvoli S, Madeddu G. The clinical impact of breast scintigraphy acquired with a breast specific γ-camera (BSGC) in the diagnosis of breast cancer: incremental value versus mammography. Int J Oncol. 2012;41(2):483–9. https://doi.org/10.3892/ijo.2012.1495 Epub 2012 May 24.
Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005;353(17):1784–92. https://doi.org/10.1056/NEJMoa050518.
Rosenberg RD, Hunt WC, Williamson MR, Gilliland FD, Wiest PW, Kelsey CA, et al. Effects of age, breast density, ethnicity, and estrogen replacement therapy on screening mammographic sensitivity and cancer stage at diagnosis:review of 183, 134 screening mammograms in Albuquerque, New Mexico. Radiology. 1998;209(2):511–8. https://doi.org/10.1148/radiology.209.2.9807581.
Boyd NF, Guo H, Martin LJ, Sun L, Stone J, Fishell E, et al. Mammographic density and the risk and detection of breast cancer. N Engl J Med. 2007;356(3):227–36. https://doi.org/10.1056/NEJMoa062790.
Barlow WE, White E, Ballard-Barbash R, Vacek PM, Titus-Ernstoff L, Carney PA, et al. Prospective breast cancer risk prediction model for women undergoing screening mammography. J Natl Cancer I. 2006;98(17):1204–14. https://doi.org/10.1093/jnci/djj331.
Yu X, Hu G, Zhang Z, Qiu F, Shao X, Wang X, et al. Retrospective and comparative analysis of 99m Tc-Sestamibi breast specific gamma imaging versus mammography, ultrasound,and magnetic resonance imaging for the detection of breast cancer in Chinese women. BMC Cancer. 2016;16:450. https://doi.org/10.1186/s12885-016-2537-1.
Kessler R, Sutcliffe JB, Bell L, Bradley YC, Anderson S, Banks KP. Negative predictive value of breast specific gamma imaging in low suspicion breast lesions: a potential means for reducing benign biopsies. Breast J. 2011;17(3):319–21. https://doi.org/10.1111/j.1524-4741.2011.01077.x Epub 2011 Apr 14.
Helvie MA, Paramagul C, Oberman HA, Adler DD. Invasive lobular carcinoma. Imaging features and clinical detection. Invest Radiol. 1991;28(3):202–7.
Spanu A, Sanna D, Chessa F, Cottu P, Manca A, Madeddu G. Breast scintigraphy with breast-specific γ-camera in the detection of ductal carcinoma in situ: a correlation with mammography and histologic subtype. J Nucl Med. 2012;53(10):1528–33. https://doi.org/10.2967/jnumed.112.103010 Epub 2012 Aug 21.
Cho MJ, Yang J-H, Yu YB, Park KS, Chung HW, So Y, et al. Validity of breast-specific gamma imaging for Breast Imaging Reporting and Data System 4 lesions on mammography and/or ultrasound. Ann Surg Treat Res. 2016;90(4):194–200. https://doi.org/10.4174/astr.2016.90.4.194.
Tadwalkar RV, Rapelyea JA, Torrente J, Rechtman LR, Teal CB, AP MS, et al. Breast-specific gamma imaging as all adjunct modality for the diagnosis of invasive breast cancer with correlation to tumor size and grade. Br JRadiol. 2012;85(1014):e212–6. https://doi.org/10.1259/bjr/34392802 Epub 2011 Jun 28.
Sampalis FS, Denis R, Picard D, Fleiszer D, Martin G, Nassif E, et al. International prospective evaluation of scintimammography with 99m-technetium sestamibi. Am J Surg. 2003;185(6):544–9.
Kim SJ, Kim IJ, Bae YT, Kim YK, Kim DS. Comparison of quantitative and visual analysis of Tc-99m MIBI scintimammography for detection of primary breast cancer. Eur J Radiol. 2005;53(2):192–8. https://doi.org/10.1016/j.ejrad.2003.10.024.
Spanu A, Chessa F, Sanna D, Cottu P, Manca A, Nuvoli S, Madeddu G. Breast cancer axillary lymph node metastasis detection by a high-resolution dedicated breast camera: a comparative study with SPECT and pinhole SPECT. Cancer Biother Radiopharm. 2007;22(6):799–811.
Yoon JH, Jung HK, Lee JT, Ko KH. Shear-wave elastography in the diagnosis of solid breast masses: what leads to false-negative or false-positive results? Eur Radiol. 2013;23(9):2432–40. https://doi.org/10.1007/s00330-013-2854-6 Epub 2013 May 15.iscussion 445–7.
Bilimoria KY, Cambic A, Hansen NM, Bethke KP. Evaluating the impact of pre-operative breast magnetic resonance imaging on the surgical management of newly diagnosed breast cancers. Arch Surg. 2007;142(5):441–5 discussion 445-7.
Fallenberg EM, Schmitzberger FF, Amer H, Ingold-Heppner B, Balleyguier C, Diekmann F, et al. Contrast- enhanced spectral mammography vs. mammography and MRI-clinical performance in a multi-reader evaluation. Eur Radiol. 2017;27(7):2752–64. https://doi.org/10.1007/s00330-016-4650-6 Epub 2016 Nov 28.
Sun Y, Wei W, Yang HW, Liu JL. Clinical usefulness of breast-specific gamma imaging as an adjunct modality to mammography for diagnosis of breast cancer: a systemic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2013;40(3):450–63. https://doi.org/10.1007/s00259-012-2279-5 Epub 2012 Nov 14.
Weigert JM, Bertrand ML, Lanzkowsky L, Stern LH, Kieper DA. Results of a multicenter patient registry to determine the clinical impact of breast-specific gamma imaging, a molecular breast imaging technique. AJR Am J Roentgenol. 2012;198(1):W69–75. https://doi.org/10.2214/AJR.10.6105.
Jones EA, Phan TD, Blanchard DA, Miley A. Breast-specific gamma-imaging: molecular imaging of the breast using 99mTc-sestamibi and a small-field-of-view gamma-camera. J Nucl Med Technol. 2009;37(4):201–5. https://doi.org/10.2967/jnmt.109.063537 Epub 2009 Nov 13.
Rhodes DJ, Hruska CB, Conners AL, Tortorelli CL, Maxwell RW, Jones KN, Toledano AY, O'Connor MK. Molecular breast imaging at reduced radiation dose for supplemental screening in mammographically dense breasts. AJR Am J Roentgenol. 2015;204(2):241–51. https://doi.org/10.2214/AJR.14.13357.
Park JS, Lee AY, Jung KP, Choi SJ, Lee SM, Kyun BS. Diagnostic performance of breast-specific gamma imaging (BSGI) for breast cancer: usefulness of dual-phase imaging with (99m)Tc-sestamibi. J Nucl Med Mol Imaging. 2013;47(1):18–26. https://doi.org/10.1007/s13139-012-0176-2 Epub 2012 Oct 13.
Ethics approval and consent to participate
This study was approved by Second Affiliated Hospital of Zhejiang University School of Medicine ethics committee and all the patients had given written informed consent.
Consent for publication
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Liu, H., Zhan, H. & Sun, D. Comparison of 99mTc-MIBI scintigraphy, ultrasound, and mammography for the diagnosis of BI-RADS 4 category lesions. BMC Cancer 20, 463 (2020). https://doi.org/10.1186/s12885-020-06938-7
- Breast-specific gamma imaging/BSGI
- Breast cancer